The problems with patenting antibodies

“When it comes to protecting biopharmaceutical inventions, particularly antibody inventions, there is definitely not a one-size-fits-all approach,” remarks Kathy Coulter, senior IP counsel at Bristol-Myers Squibb (BMS) in San Francisco.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AI, anxiety, and antibodies: The issues dominating life sciences

26 May 2026 Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.

Americas

How should in-house teams adopt AI? ‘Carefully’, says secrets expert

26 May 2026 Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.

Americas

Lupin scores another win in kidney drug dispute

22 May 2026 A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.

More features

Takeda’s China IP head: What pharma is still getting wrong

Boehringer Ingelheim adds ex-Teva executive to patent team

AI, anxiety, and antibodies: The issues dominating life sciences

How should in-house teams adopt AI? ‘Carefully’, says secrets expert

Lupin scores another win in kidney drug dispute

Battle over inhaler shape ends badly for Boehringer

Healthcare leads sweeping AI partnership in Singapore

Jones Day adds in-house biologics specialist to Boston office

The problems with patenting antibodies

More on this story

Editor's picks

Editor's picks

More features